Bioharvest Stock Price, News & Analysis

BioHarvest Sciences (NASDAQ: BHST) on December 3, 2025 launched VINIA Blood Flow Hydration, a hydration stick-pack powered by VINIA's Piceid resveratrol and red-grape polyphenols entering the $13 billion U.S. electrolyte drink market. The formula delivers 23 mg red-grape polyphenols including 6 mg rapid-absorption Piceid resveratrol, plus naturally sourced electrolytes: 470 mg sodium, 190 mg potassium, and 80 mg magnesium per serving. The product is shipping nationwide via VINIA.com with free North America delivery, will appear on Amazon by end of December 2025, is Informed Sport tested, and is backed by a 90-day “Feel It or It’s Free” guarantee. Clinical support is cited from Vaisman et al., 2015.

BioHarvest Sciences (NASDAQ: BHST) reported third quarter 2025 results: revenue $9.1M, +39% YoY, gross profit $5.6M (61% margin), and a net loss of $2.5M or $0.14 per share. Management expects Q4 2025 revenue of $9.0–9.5M and adjusted EBITDA of ($0.6)–$0.0M.

Operational highlights include a VINIA user base >75,000, a VIP early adopter launch of VINIA Blood Flow Hydration (market rollout Dec 3), a breakthrough producing plant-based exosomes at scale, and a new CDMO customer (Saffron Tech) with BioHarvest retaining 25% ownership of the compound. The company strengthened its balance sheet via accelerated warrant exercises and debt conversions and a $19.9M institutional equity raise in November.

BioHarvest Sciences (NASDAQ: BHST) announced management will attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025 in New York.

CEO Ilan Sobel is scheduled for one-on-one investor meetings at the Sheraton New York Times Square. The company highlighted momentum in its consumer VINIA® capsule business, new product lines (VINIA® Daily Chews 2X Formula and VINIA® Blood Flow Hydration Solution), CDMO milestones including a plant-based exosome production breakthrough and a new saffron compound development contract, and the close of an upsized $19.9 million equity offering led by Craig-Hallum. Management cited a focus on delivering adjusted EBITDA breakeven in the near term. Registration is mandatory; meetings arranged via MZ Group at BHST@mzgroup.us.

BioHarvest Sciences (NASDAQ: BHST) closed an upsized underwritten public offering of 2,846,854 common shares at a public offering price of $7.00 per share, including 361,854 shares issued upon exercise of the underwriters' option. Gross proceeds were $19.9 million before underwriting discounts and offering expenses. Craig-Hallum served as sole managing underwriter.

The company said net proceeds will fund additional manufacturing expansion, R&D, marketing, debt reduction or refinancing, capital expenditures, and working capital. Management plans to provide updates on strategic initiatives during its third quarter earnings call on November 13, 2025.

BioHarvest Sciences (NASDAQ: BHST) priced an underwritten public offering of 2,485,000 common shares at $7.00 per share, for gross proceeds of about $17.4 million, before underwriting discounts and expenses.

The company granted the underwriters a 30-day option to buy up to 372,750 additional shares at the public price less the underwriting discount. BioHarvest expects to close the offering on or about November 10, 2025, with Craig-Hallum as sole managing underwriter.

Net proceeds are expected to be used for R&D, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes. The offering is made under a Form F-3 shelf registration declared effective on September 8, 2025.

BioHarvest (NASDAQ: BHST) announced on November 6, 2025 its intent to conduct an underwritten public offering of common stock, with Craig-Hallum as sole managing underwriter.

The company said it may grant the underwriter a 30-day option to buy up to an additional 15% of the shares. Proceeds are expected to be used for R&D, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes. The offering is subject to market conditions and filing of a preliminary prospectus supplement to the SEC.

BioHarvest Sciences (NASDAQ: BHST) will release third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 13, 2025. Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on November 13 to discuss Q3 2025 results, provide a corporate update, and hold a Q&A session for telephone participants.

Call details: U.S./Canada dial-in 1-877-300-8521; international dial-in 1-412-317-6026; conference ID 6486821. A telephone playback will be available through Thursday, November 27, 2025 (U.S./Canada replay 1-844-512-2921; international 1-412-317-6671; replay PIN 10204225). A webcast and replay will be available via the company webcast link.

BioHarvest Sciences (NASDAQ: BHST) entered a strategic CDMO partnership with Saffron Tech to develop and commercialize saffron-derived compounds using BioHarvest's patented Botanical Synthesis platform.

Key terms: Saffron Tech will own 75% of developed compositions and IP, BioHarvest will retain 25%. BioHarvest expects Q3 2025 revenue ≈ $9.1M, adjusted EBITDA of ($0.7M) to ($0.4M), cash ≈ $11M as of Sept 30, 2025, and Q4 2025 guidance of $9.0–$9.5M revenue with adjusted EBITDA ($0.6M) to $0.0M. Management highlighted VINIA and CDMO growth and a VINIA BloodFlow Hydration launch on Nov 7, 2025.

BioHarvest Sciences (NASDAQ:BHST) has significantly strengthened its financial position through a series of transactions totaling $14.7 million in balance sheet improvements. The biotechnology company secured $10.9 million in gross proceeds through warrant exercises and convertible note issuances, while simultaneously reducing debt by $3.8 million.

The transactions included $5.8 million raised through warrant exercises, $5.1 million from new convertible notes, and various debt conversions and repayments. The company offered warrant holders and convertible loan holders a reduced price of $6.50 per share. Following these transactions, BioHarvest's total debt stands at $6.6 million.

The proceeds will fund capital expenditures for new capacity building, debt refinancing, and working capital requirements.